Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Yuhan Replaces Merck To Market Samsung’s Biosimilars In Korea

Oct 12 2017

• By Jung Won Shin

Samsung Bioepis

Related Content

CHMP OKs First EU Biosimilar Herceptin, And Another Version Of Humira

Sep 15 2017

Samsung Bioepis Builds Its Biosimilars Name In Europe

Aug 28 2017

Related Companies

Samsung Bioepis Co., Ltd.

Yuhan Corporation

Merck & Co., Inc.

Samsung Bioepis Co., Ltd.

Biogen, Inc.

Pfizer Inc.

Johnson & Johnson

Additional Topics

South Korea Asia Pacific Commercial Biosimilars Business Strategies BioPharmaceutical

More from Business

More from Generics Bulletin

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window